长春高新：控股子公司获得《药物临床试验批准通知书》

Group 1 - The core revenue composition of Changchun High-tech for the year 2024 is as follows: 94.07% from the pharmaceutical industry, 5.61% from real estate, and 0.32% from the service industry [1] - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its drug, Kamexoline Tablets [3]